| Schedule of research and development costs |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended | | Three Months Ended | | Nine Months Ended | | Nine Months Ended | | | September 30, 2026 | | September 30, 2025 | | September 30, 2026 | | September 30, 2025 | | | | (In thousands) | Barzolvolimab/Anti-KIT Program | | $ | 53,517 | | $ | 51,619 | | $ | 170,627 | | $ | 133,967 | CDX-622 | | | 3,794 | | | 5,617 | | | 11,590 | | | 14,906 | Other Programs (a) | | | 10,096 | | | 5,695 | | | 25,733 | | | 20,868 | Total R&D Expense | | $ | 67,407 | | $ | 62,931 | | $ | 207,950 | | $ | 169,741 |
| (a) | Other program expenses primarily include research and development expenses related to early-stage programs, revenue-generating programs and discontinued programs. |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended | | Three Months Ended | | Nine Months Ended | | Nine Months Ended | | | September 30, 2026 | | September 30, 2025 | | September 30, 2026 | | September 30, 2025 | | | | (In thousands) | Personnel | | $ | 18,272 | | $ | 14,455 | | $ | 49,726 | | $ | 42,184 | Laboratory supplies | | | 2,138 | | | 1,057 | | | 6,188 | | | 4,769 | Facility | | | 1,422 | | | 1,410 | | | 3,540 | | | 4,214 | Product development (b) | | | 38,401 | | | 42,371 | | | 130,304 | | | 108,073 | Other expenses (c) | | | 7,174 | | | 3,638 | | | 18,192 | | | 10,501 | Total R&D expense | | $ | 67,407 | | $ | 62,931 | | $ | 207,950 | | $ | 169,741 |
| (b) | Product development expenses include clinical investigator site fees, external trial monitoring costs, data accumulation costs, contracted research and outside clinical drug product manufacturing. |
| (c) | Other expenses primarily include research and development consulting, insurance, licensing and software expenses. |
|